Opinion|Videos|October 25, 2024
Navigating the Challenges: Transitioning Patients from Community to Academic Settings in Multiple Myeloma Care
Panelists discuss how transitioning patients with multiple myeloma from community to academic settings faces challenges including communication gaps, differences in treatment approaches, patient reluctance, and logistical hurdles.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are some challenges you are seeing when transitioning from community to academic settings
Advertisement
Related to this article
Ralph V. Boccia, MD, FACP, discusses step-up dosing workflows, REMS, staff training, caregivers, and hospital partnerships for bispecifics.
Ralph V. Boccia, MD, FACP, discusses CAR T and bispecific sequencing, fixed-duration therapy, MRD, and bispecifics in AL amyloidosis.
Jeffrey V. Matous, MD, explains why ramantamig’s MRD negativity rates are clinically significant in relapsed/refractory myeloma.
Experts in multiple myeloma discussed long-term MAIA and CEPHEUS trial data and their implications for daratumumab-based regimens in newly diagnosed disease.
Jeffrey V. Matous, MD, discusses how to counsel patients on chronic, low-grade toxicities to support adherence to ramantamig.
Iberdomide plus daratumumab/dexamethasone met the second dual primary end point of the phase 3 EXCALIBER-RRMM trial in relapsed/refractory multiple myeloma.
Experts discuss data from the MonumenTAL-3 trial and the evolving roles of talquetamab and other bispecific antibodies in relapsed/refractory multiple myeloma.
Natalie S. Callander, MD, discussed the rationale for combining selinexor, carfilzomib, subcutaneous isatuximab, and dexamethasone in relapsed/refractory myeloma.
Advertisement
Advertisement
Trending on CancerNetwork
1
Sequencing Bispecifics and CAR T-Cell Therapy in Myeloma and AL Amyloidosis
2
Novel Cancer Vaccine Plus Temozolomide Miss Primary End Point in Glioblastoma
3
Early Treatment Support and Real-World Care Gaps
4
FDA Approves Atezolizumab/Chemo for Stage III dMMR Colon Cancer
5